Department of Radiation Biology

Latest Publications


Michaelsen SR, Staberg M, Pedersen H, Jensen KE, Majewski W, Broholm H, Nedergaard MK, Meulengracht C, Urup T, Villingshøj M, Lukacova S, Skjøth-Rasmussen J, Brennum J, Kjær A,
Lassen U, Stockhausen MT, Poulsen HS, Hamerlik: VEGF-C Sustainns VEGFR2 Activation under Bevacizumab therapy and promotes Glioblastoma Maintenance. Neuro Oncol. 2018 Jun 25. doi::10.1093/neuonc/noy103. [Epub ahead of print] PMID: 29939339. (Click here to open pubmedlink)
Jakobsen JN, Urup T, Grunnet K, Toft A, Johansen MD, Poulsen SH, Christensen IJ, Muhic A, Poulsen HS: Toxicity and efficacy of lomustine and bevacizumab in recurrent glioblastoma patients.J Neurooncol. 2018 Apr;137(2):439-446. doi: 10.1007/s11060-017-2736-x. Epub 2018 Jan 12. PMID: 29330749. (Click here to open pubmedlink)
Staberg M, Rasmussen RD, Michaelsen SR, Pedersen H, Jensen KE, Villingshøj M, Skjoth-Rasmussen J, Brennum J, Vitting-Seerup K, Poulsen HS, Hamerlik P: Targeting glioma stem-like cell survival and chemoresistance through inhibition of lysine-specific histone demethylase KDM2B.Mol Oncol. 2018 Mar;12(3):406-420. doi: 10.1002/1878-0261.12174. Epub 2018 Feb 12. PMID: 29360266. (Click here to open pubmedlink)
Toft A, Urup T, Christensen IJ, Michaelsen SR, Lukram B, Grunnet K, Kosteljanetz M, Larsen AVA, Lassen U, Broholm H, Poulsen HS: Biomarkers in Recurrent Grade III Glioma Patients Treated with Bevacizumab and Irinotecan. Cancer Invest. 2018 Feb 7;36(2):165-174. doi: 10.1080/07357907.2018.1430818. Epub 2018 Feb 2. Reveiw PMID: 29393706. (Click here to open pubmedlink)
Michaelsen SR, Aslan D, Urup T, Poulsen HS, Grønbæk K, Broholm H, Kristensen LS: DNA Methylation Levels of the ELMO Gene Promoter CpG Islands in Human Glioblastomas. Int J Mol Sci. 2018 Feb 28;19(3). pii: E679. doi: 10.3390/ijms19030679.PMID: 29495584. (Click here to open pubmedlink)
Urup T, Staunstrup LM, Michaelsen SR, Vitting-Seerup K, Bennedbæk M, Toft A, Olsen LR, Jønson L, Issazadeh-Navikas S, Broholm H, Hamerlik P, Poulsen HS, Lassen U. Transcriptional changes induced by bevacizumab combination therapy in responding and non-responding recurrent glioblastoma patients. BMC Cancer. 2017 Apr 18;17(1):278. doi: 10.1186/s12885-017-3251-3. PMID: 28420326.  (Click here to open pubmedlink)
Lundemann M, Costa J, Law I, Engelholm SA, Muhic A, Poulsen HS, Rosenschold PM:Patterns of failure for patients with glioblastoma following O-(2-[18F] fluoroethyl)-L-tyrosine PET- and MRI-guided radiation therapy. Radiother Oncol. 2017 Jan 19. pii: S0167-8140(17)30007-5. Doi 10.1016 PMID: 28110959 (Click here to open pubmedlink)
Staberg M, Michaelsen SR, Rasmussen RD, Villingshøj M, Poulsen HS, Hamerlik P: Inhibition of histone deacetylases sensitizes glioblastoma cells to Lomustine. Cell Oncol (Dordr). 2016 Oct 20. PMID: 27766591. (Click here to open pubmed link)
Møller S, Law I, Rosenschold PM, Costa J, Poulsen HS, Engelholm SA, Engelholm S: Prognostic value of 18F-FET PET imaging in reirradiation of high-grade glioma: Results of a prospective trial. Radiotherapy and Oncology, 2016 Oct;121(1) 132-137.Doi 10.1016, PMID: 27622554 (Click here to open pubmed link)
Urup T, Michaelsen SR, Olsen LR, Toft A, Christensen IJ, Grunnet K, Winther O, Broholm H, Kosteljanetz M, Issazadeh-Navikas S, Poulsen HS, Lassen U: Angiotensinogen and HLA Class II Predict Bevacizumab Response in Recurrent Glioblastoma Patients. Mol Oncol. 2016 Oct;10(8):1160-8. doi: 10.1016 PMID: 27262894 (Click here to open pubmed link)
Poulsen SH, Urup T, Grunnet K, Christensen IJ, Larsen VA, Rosenschöld PM, Poulsen HS, Law I: The prognostic value of radiotherapy planning O-(2-18F-fluoroethyl)-L-tyrosine PET in newly
diagnosed glioblastoma. Eur J Nucl Med Mol Imaging. 2016 Aug 23, PMID: 27554774 (Click here to open pubmed link)
Staberg M, Michaelsen SR, Olsen LS, Nedergaard MK, Villingshøj M, Hamerlik P, Poulsen HS: Combined EGFR- and Notch inhibition display additive inhibitory effect on Glioblastoma cell viability and Glioblastoma-induced endothelial cell sprouting in vitro. Cancer Cell Int.2016 Apr 26; 16:34. doi: 10.1186. PMID: 27118928 (Click here to open pubmed link)
Johansen MD, Rochat P, Law I, Scheie D, Poulsen HS, Muhic A:
Presentation of Two Cases with Early Extracranial Metastases from Glioblastoma and Review of the Literature.Case Reports in Oncological Medicine Volume 2016. (Click here to open pubmed link)
Campos B, Olsen LR, Urup T, Poulsen HS. A comprehensive profile of recurrent glioblastoma. Oncogene. 2016 Apr 4. doi: 10. PMID: 27041580.(Click here to open pubmed link)
Nedergaard MK, Michaelsen SR, Perryman L, Erler J, Poulsen HS, Stockhausen MT, Lassen U, Kjaer A. Comparison of (18)F-FET and (18)F-FLT small animal PET for the assessment of anti-VEGF treatment response in an orthotopic model of glioblastoma.
Nucl Med Biol. 2016 Mar;43(3):198-205. (Click here to open pub med link)
Kristensen LS, Michaelsen SR, Dyrbye H, Aslan D, Grunnet K, Christensen IJ, Poulsen HS, Grønbæk K, Broholm H: Assessment of Quantitative and Allelic MGMT Methylation Patterns as a Prognostic Marker in Glioblastoma.
J Neuropathol Exp Neurol. 2016 Feb 16.  (Click here to open pub med link)

Urup T, Dahlrot RH, Grunnet K, Christensen IJ, Michaelsen SR, Toft A, Larsen VA, Broholm H, Kosteljanetz M, Hansen S, Poulsen HS, Lassen U.Development and validation of a prognostic model for recurrent glioblastoma patients treated with bevacizumab and irinotecan. Acta Oncol. 2016 Apr;55(4):418-22.  (Click here to open pub med link)
Persson M, Nedergaard M, Brandt-Larsen M, Skovgaard D, Jørgensen JT, Michaelsen SR, Madsen J, Lassen U, Poulsen HS, Kjaer A: uPAR is a Promising New Imaging Biomarker in Glioblastoma. J Nucl Med. 2015 Oct 1. pii: jnumed.115.161703. (click here to open pubmed link)
Henriksen OM, Larsen VA, Muhic A, Hansen AE, Larsson HB, Poulsen HS, Law I: Simultaneous evaluation of brain tumour metabolism, structure and blood volume using [18F]-fluoroethyltyrosine (FET) PET/MRI: feasibility, agreement and initial experience.
Eur J Nucl Med Mol Imaging. 2015 Sep 12. (click here to open pubmed link)
Møller S, Lundemann M, Law I, Poulsen HS, Larsson HB, Engelholm SA: Early changes in perfusion of glioblastoma during radio- and chemotherapy evaluated by T1-dynamic contrast enhanced magnetic resonance imaging. Acta Oncol. 2015 Jul 23:1-8 (click here to open pubmed link)
Nedergaard MK, Michaelsen SR, Urup T, Broholm H, El Ali H, Poulsen HS, Stockhausen MT, Kjaer A and Lassen U: 18F-FET MicroPET and MicroMRI for anti-VEGF and anti-PlGF response assessment in an orthotopic murine model of human glioblastoma: PLoS One. 2015 Feb 13:10(2) (click here to open pubmed link)
Lassen U, Mau-Sørensen M, Poulsen HS: Orphan drugs in development for glioblastoma multiforme: a review. Orphan Drugs: Research and Reviews, nov.2014, 4:83-91(click here to open pubmed link)
Christensen CL, Kwiatkowski N, Abraham BJ, Carretero J, Al-Shahrour F, Zhang T, Chipumuro E, Herter-Sprie GS, Akbay EA,Altabef A, Zhang J, Shimamura T, Capelletti M, Reibel JB, Cavanaugh JD, Gao P, Liu Y, Michaelsen SR, Poulsen HS, Aref AR, Barbie DA,. Bradner JE, George RE, Gray NS, Young RA, Kwok-Kin Wong KK: Targeting Transcriptional Addictions in Small Cell Lung Cancer with a Covalent CDK7 Inhibitor:Cancer Cell; Volume 26, Issue 6, 8 December 2014, Pages 909–922
Poulsen HS, Urup T, Michaelsen SR, Staberg M, Villingshøj M, Lassen U: The impact of bevacizumab treatment on survival and quality of life in newly diagnosed glioblastoma patients. Cancer Manag Res.2014:6 373–387.(click here to open pubmed link)
Nedergaard MK, Kristoffersen K, Michaelsen SR, Poulsen HS, Stockhausen MS, Lasse U, Kjaer A: The use of longitudinal 18F-FET MicroPET imaging to evaluate response to irinotecan in orthotopic human glioblastoma multiforme xenografts. PLoS One. 2014; 9(6): e100009. (click here to open pubmed link)
Kristoffersen K, Nedergaard MK, Villingshøj M, Borup R, Broholm H, Kjær A, Poulsen HS,
Stockhausen MT: Inhibition of Notch signaling alters the phenotype of orthotopic tumors formed from glioblastoma multiforme neurosphere cells but does not hamper intracranial tumor growth regardless of endogene Notch pathway signature. Cancer Biol Ther. 2014 Apr 22;15(7). (click here to open pubmed link)
Hofland KF, Hansen S, Sorensen M, Schultz HP, Muhic A, Engelholm S, Grunnet K, Ask A,
Kristiansen C, Thomsen C, Poulsen HS, Lassen U: Neoadjuvant Bevacizumab and Irinotecan versus Bevacizumab and Temozolomide followed by Concomitant Chemoradiotherapy in Newly Diagnosed Glioblastoma Multiforme: A Randomized Phase II Study. Acta Oncol. 2014 Jan 23.(click here to open pubmed link)

Stockhausen MT, Kristoffersen K, Olsen MLS, Poulsen HS: Differentiation of human glioblastoma multiforme stem-like cells leads to down regulation of EGFR and EGFRvIII expression and decreased tumorigenic and stem cell potential. Cancer Biol Ther. 2014 Feb 1;15(2):216-24.(click here to open pubmed link) 


Michaelsen SR, Christensen IJ, Grunnet K, Stockhausen MT, Broholm H, Kostaljanetz M, Poulsen HS: Clinical variables serve as prognostic factors in a model for survival from glioblastoma multiforme in a cohort of consecutive non-selected patients from a single institution. BMC Cancer. 2013 Sep 3;13(1):402.(click here to open pubmed link)

Kristoffersen K, Villingshøj M, Poulsen HS, Stockhausen MT: Level of Notch activation determines the effect on growth and stem cell-like features in glioblastoma multiforme neurosphere cultures.
Cancer Biol Ther. 2013 Jul 1;14(7):625-37.(click here to open pubmed link)

Lassen U, Sørensen M, Gaziel, TB, Hasselbalch B, Poulsen HS: Phase II study of bevacizumab and Temsirolimus combination therapy for recurrent glioblastoma multiforme. Anticancer Research, 2013 Apr;33(4):1657-60.(click here to open pubmed link)

Muhic A, Poulsen HS, Sorensen M, Grunnet K, Lassen U: Phase II Open-label Study of Nintedanib in Patients with Recurrent Glioblastoma Multiforme.
J Neurooncol. Jan;111(2):205-12.2013(click here to open pubmed link)  


Bondgaard ALRØ, Poulsen TT, Poulsen HS, Skov BG: Different Expression of EZH2, BMI1 and Ki67 in Low and High Grade Neuroendocrine Tumors of the Lung.
Cancer Biomark;11(2-3):123-8.2012(click here to open pubmed link)

Cramer F, Christensen CL, Poulsen TT, Badding MA, Dean DA, Poulsen HS:
Insertion of a Nuclear Factor Kappa B DNA Nuclear Targeting Sequence potentiates
suicide gene therapy efficacy in lung cancer cell lines. Cancer Gene Therapy Oct;19(10):675-83. 2012 (click here to open pubmed link)

Møller S, Grunnet K, Hansen S, Schultz H, Holmberg M, Sorensen M, Poulsen HS, Lassen U: A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and
progression after standard therapy. Acta Oncol. Jul;51(6):797-804, 2012.(click here to open pubmed link)

Michaelsen SR, Christensen CL, Sehested M, Cramer F, Poulsen TT, Patterson AV, Poulsen HS.: Single agent- and combination treatment with two targeted suicide gene therapy systems is effective in chemo-resistant small cell lung cancer (SCLC) cells.
J Gene Med. Jul;14(7):445-58, 2012  (click here to open pubmed link) 

Stockhausen MT, Kristoffersen K, Poulsen HS: Notch signaling and brain tumors. Adv Exp Med Biol.727:289-30, 2012 (click here to open pubmed link)

Poulsen HS, Von der Maase H.: MiRNA ved glioblastomer - potentiale og begrænsninger. Ugeskr. Læger,Marts 5; 174(10): 628, 2012 (click here to open link)

Nedergaard MK, Hedegaard CJ, Poulsen HS: Targeting the Epidermal growth factor receptor in solid tumor malignancies. BioDrugs: Apr 1;26(2):83-99. 2012 (click here to open pubmed link)


Zandi R, Xu K, Poulsen HS, Roth JA and Ji L: Overexpression of the novel tumor suppressor gene FUS1 suppresses the growth of small cell Lung cancer cells. Clinical and Experimental Pathology. J Clinic Experiment Pathol S5, 12/2011(click here to read article)

Zandi R, Xu K, Poulsen HS, Roth JA and Ji L: The effect of adenovirus-mediated gene expression of FHIT in small cell lung cancer cells.
Cancer Investigation, 29(10):683–691, 2011 (click here to open pubmed link)

Gjetting T, Andresen TL, Christensen CL, Poulsen TT, Cramer F, Poulsen HS : A simple protocol for preparation of a liposomal vesicle with encapsulated plasmid DNA that
mediate high accumulation and reporter gene activity in tumor tissue. Results in Pharma Sciences 1 (2011): 49-56. (click here to read article)

Stockhausen MT, Broholm H, Villingshøj M, Kirchhoff M, Gerdes T, Kristoffersen K, Kosteljanetz M, Spang-Thomsen M, and Poulsen HS: Maintenance of EGFR and EGFRvIII expression in an in vivo and in vitro model of human glioblastoma multiforme. Experimental Cell Research 2011. Jul 1; 317(11):1513-26.(click here to open pubmed link)

Zandi R, Selivanova G, Christensen CL, Gerds TA, Willumsen BM, Poulsen HS:”PRIMA-1Met/APR-246 induces apoptosis and tumor growth delay in Small Cell Lung Cancer expressing mutant p53”. Clin Cancer Research, 2011 May 1; 17(9):2830-41.(click here to open pubmed link)

Denholt C, Binderup T, Stockhausen MT, Poulsen HS, Spang-Thomsen, Hansen PR, Gillings N, Kjær A: Evaluation of 4-[18F]fluorobenzoyl-FALGEA-NH2 as a Positron Emission Tomography tracer for epidermal growth factor receptor mutation variant III imaging in cancer. Nuclear Medicine and Biology. 2011 May; 38(4):509-15. (click here to open pubmed link)

Henriksson R, Asklund T, Poulsen HS: Impact of therapy on quality of life, neurocognitive function and their correlates in Glioblastoma Multiforme. J. Neurooncol. 2011 Apr 6. (click here to open pubmed link)

Jakobsen JN, Hasselbalch B, Stockhausen MT, Lassen U, Poulsen HS: Irinotecan and bevacizumab treatment of recurrence of Glioblastoma Multiforme. Expert Opinion On Pharmacotherapy, 2011. 2011 Apr;12(5):825-33.(click here to open pubmed link)

Hasselbalch B, Lassen U, Poulsen HS. Patients with Recurrent High-Grade Glioma. Therapy with Combination of Bevacizumab and Irinotecan. In: M.A. Hayat, Tumors of the central nervous system. Volume 2. Springer 2011, pp 289-301.

Stockhausen MT, Kristoffersen K, Poulsen HS. Notch Signaling and Brain Tumors. In: Reichrath J and Reichrath S. Notch Signaling in Embryology and Cancer. Landes Bioscience and Springer, 2011.


Olszewski U, Poulsen TT, Ulsberger E, Poulsen HS, Geissler K, Hamilton G. In vitro cytotoxity of combinations of dichloroacetate with anticancer platinum compounds. Clinical Pharmacology. Advances and Applications 2010:2 1-7
(click here to open pubmed link)

Gjetting T, Arildsen NS, Christensen CL, Poulsen TT, Roth JA, Handlos VN, Poulsen HS. In vitro and in vivo effects of polyethylene glycol (PEG)-modified lipid in DOTAP/cholesterol-mediated gene transfection. Int. J. Nanomedicine 2010, Aug 9;5:371-83
(click here to open pubmed link)

Hasselbalch B, Eriksen JG, Broholm H, Christensen IJ, Grunnet K, Horsman MR, Poulsen HS, Stockhausen MT, Lassen U. Prospective evaluation of angiogenic, hypoxic and EGFR related biomarkers in recurrent glioblastoma multiforme treated with cetuximab, bevacizumab and irinotecan. APMIS 2010 Aug.
(click here to open pubmed link)

Bartkova J, Hamerlik P, Stockhausen MT, Ehrmann J, Hlobilkova A, Laursen H, Kalita O, Kolar Z, Poulsen HS, Broholm H, Lukas J, Bartek J. Replication stress and oxidative damage contribute to aberrant constitutive activation of DNA damage signalling in human gliomas. Oncogene. 2010 Jun 28.
(click here to open pubmed link)

Hasselbalch B, Lassen U, Poulsen HS, Stockhausen MT. Cetuximab Insufficiently Inhibits Glioma Cell Growth Due to Persistent EGFR Downstream Signaling. Cancer Invest. 2010 May 26.
(click here to open pubmed link)

Madsen K, Poulsen HS. Needs for everyday life support for brain tumour
patients' relatives: systematic literature review. Eur J Cancer Care (Engl). 2010 Apr 30. (click here to open pubmed link)

Benedikte Hasselbalch, Ulrik Lassen, Steinbjørn Hansen, Mats Holmberg, Morten Sørensen, Michael Kosteljanetz, Helle Broholm, Marie-Thérése
Stockhausen, and Hans Skovgaard Poulsen. Cetuximab, bevacizumab, and
irinotecan for patients with primary glioblastoma and progression after
radiation therapy and temozolomide: a phase II trial. Journal of Neuro-Oncology, 2010;12(5):508-516 (click here to open pubmed link)

Christensen CL, Gjetting T, Poulsen TT, Cramer F, Roth JA, Poulsen HS.  Targeted Cytosine Deaminase-Uracil Phosphoribosyl Transferase Suicide Gene Therapy Induces Small Cell Lung Cancer-Specific Cytotoxicity and Tumor Growth Delay. Clin Cancer Res. 2010 Apr 6, 20371678 (click here to open pubmed link)

Kosteljanetz M, Poulsen HS. Ugeskrift for Læger. 2010 Jan 18;172(3):214-217.
(click here to open pubmed link)

Marie-Thérése Stockhausen, Karina Kristoffersen, Hans S. Poulsen: The
functional role of Notch Signaling in human gliomas. Journal of
Neuro-Oncology, 2010;12(2):199-211
(Click here to open pubmed link)

Larsen AB, Stockhausen MT, Skovgaard H. Cell adhesion and EGFR activation
regulate EphA2 expression in cancer. Cellular Signalling, 2010;22, 636-644.
(click here to open pubmed link).


Poulsen HS, Grunnet K, Sorensen M, Olsen P, Hasselbalch B, Nelausen K,
Kosteljanetz M, Lassen U. Bevacizumab plus irinotecan in the treatment
patients with progressive recurrent malignant brain tumours. Acta Oncol,
2009; 48: 52-58. (click here to open pubmed link).

Camilla L. Christensen, Roza zandi, Torben Gjetting, Frederik Cramer, Hans S. Poulsen: Specifically targeted gene therapy for Small Cell Lung Cancer. Expert Review for Anticancer Therapy. Expert Rev. Anticancer Ther., 9 (4), 437-452 (2009). (click here to open pubmed link)

Denholt CL, Hansen PR, Pedersen N, Poulsen HS, Gillings N, Kjaer A.
Identification of novel peptide ligands for the cancer-specific receptor mutation EFGRvIII using a mixture-based synthetic combinatorial library. Biopolymers. 2009 Mar;91(3):201-6 (click here to open pubmed link)

Andersen P, Villingshøj M, Poulsen HS, Stockhausen MT.Improved Response by
Co-targeting EGFR/EGFRvIII and Src Family Kinases in Human Cancer Cells.
Cancer Invest. 2009 Feb;27(2):178-83 (click here to open pubmed link)


Hansen CL, Hansen PR, Pedersen N, Poulsen HS, Gillings N, Kjaer A. Identification of amino acid residues in PEPHC1 important for binding to the tumor-specific receptor EGFRvIII. Chem Biol Drug Des . 2008 Oct; 72 ( 4 ): 273-8 (click here to open pubmed link)

Poulsen TT, Naizhen X, Poulsen HS, Linnoila RI. Acute damage by naphthalene triggers expression of the neuroendocrine marker PGP9.5 in airway epithelial cells. Toxicology Letters , 181 (2): 67-74, 2008 (click here to open pubmed link)

Poulsen TT, Pappot H, Poulsen HS. Molecular Biology in Lung Cancer. Chapter 3 in IASLC Textbook on Lung Cancer 2nd edition, edited by Hansen HH, Informa Healthcare, London, UK

Poulsen TT, Pedersen N, Juel H, Poulsen HS. A chimeric fusion of the hASH1 and EZH2 promoters mediates high and specific reporter and suicide gene expression and cytotoxicity in small cell lung cancer cells . Cancer Gene Therapy, 15 (9):563-75. (click here to open pubmed link)

Andersen P, Pedersen MW, Woetmann A, Villingshøj, M, Stockhausen M, Ødum N and Poulsen HS. EGFR induces expression of IRF-1 via STAT1 and STAT3 activation leading to growth arrest of human cancer cells. Int. J. Cancer, 122(2):342-9, 2008. (click here to open pubmed link)


Zandi R, Larsen AB, Andersen P, Stockhausen MT, Poulsen HS. Mechanisms for Oncogenic Activation of the Epidermal Growth Factor Receptor. Cellular Signalling, 19(10): 2013-2023, 2007. (click here to open pubmed link)

Grandal MV, Zandi R, Pedersen MW, Willumsen BM, Van Deurs B, Poulsen HS. EGFRvIII escapes downregulation due to impared internalization and sorting to lysosomes. Carcinogenesis, 28(7):1408-17, 2007 (click here to open pubmed link)

Larsen AB, Pedersen MW, Stockhausen M, Grandal MV, van Deurs B, Poulsen HS. Activation of the EGFR target gene EphA2 inhibits EGF-induced cancer cell motility. Mol Cancer Res, Mar;5(3):283-293, 2007. (click here to open pubmed link)

N. Pedersen, T.T. Poulsen, H. Skovgaard Poulsen. Cre/loxP recombination vectors for promoter studies. Electron J Biotechol, 10:315-321, 2007. (click here to read article)


Villingshoj M, Ross L, Thomsen BL, Johansen C. Does marital status and altered contact with the social network predict colorectal cancer survival? Eur J Cancer. Nov;42(17):3022-7, 2006. (click here to open pubmed link)

Spindler K-LG, Olsen DA. Nielsen JN, Brandslund I, Poulsen HS, Villingshøj M, Jakobsen A. Lack of the Type III Epidermal Growth Factor Receptor Mutation in Colorectal Cancer. Anticancer Res., Nov-Dec; 26(6C):4889-4893, 2006. (click here to open pubmed link)

Andersen PB, Blinkenberg M, Lassen U, Kosteljanetz M, Wagner A, Poulsen HS, Sorensen PS, Paulson OB. A prospective PET study of patients with glioblastoma multiforme. Acta Neurol Scand, 113(6):412-8, 2006. (click here to open pubmed link)

Poulsen HS. Gliomer hos voksne: Primær ikke-kirurgisk behandling. Ugeskr Læger, 168(47):4082, 2006. (click here to open pubmed link)

Pedersen M.W., Poulsen HS. Mutationer i EGF receptoren: struktur og tumorbiologisk relevans. Ugeskr Læger, 168:2354-2361, 2006. (click here to open pubmed link)

J. Vestergaard, M.W. Pedersen, N. Pedersen, C. Ensinger, Z. Tümer, N. Tommerup, H. Skovgaard Poulsen, L.A. Larsen: Hedgehog signaling in small-cell lung cancer: frequent in vivo but a rare event in vitro. Lung Cancer, 52:281-90, 2006. (click here to open pubmed link)

N. Pedersen, S.E. Hansen, A.V. Heydenreich, H.G. Kristensen, H. Skovgaard Poulsen: Solid lipid nanoparticles can effectively bind DNA, streptavidin and biotinylated ligands. Eur J Pharm Biopharm, 62:155-162, 2006. (click here to open pubmed link)

Pedersen N, Pedersen MW, Lan MS, Breslin MB, Poulsen HS. The Insulinoma-Associated 1: a Novel Promoter for Targeted Cancer Gene Therapy for Small Cell Lung Cancer. Cancer Gene Ther, 13:375-384, 2006. (click here to open pubmed link)


Pedersen MW, Pedersen N, Ottesen, LH, Poulsen HS. Differential response to gefinitib of cells expressing normal EGFR and the mutant EGFRvIII. Br J Cancer, 93:915-23, 2005. (click here to open pubmed link)

Poulsen TT, Pedersen N, Perin MS, Hansen CK, Poulsen HS. Specific sensitivity of small cell lung cancer cell lines to the snake venom Toxin, Taipoxin. Lung Cancer, 50 (3):329-337, 2005. (click here to open pubmed link)

Pedersen MW, Pedersen N, Damstrup L, Villingshøj M, Sønder SU, Rieneck K, Bovin LF, Poulsen HS. Analysis of the epidermal growth factor receptor specific transcriptome: effect of expression level and an activating mutation. J Cell Biochem, 96(2):412-27, 2005. (click here to read supplementary data) (click here to open pubmed link)

H. Collatz Christensen, J. Schüz, M. Kosteljanetz, H. Skovgaard Poulsen, J. D. Boice, Jr., J. K. McLaughlin and C. Johansen. Cellular telephones and risk for brain tumors. Neurology, 64:1189-1195, 2005. (click here to open pubmed link)

Poulsen TT, Pedersen N, Poulsen HS. Replacement and suicide gene therapy for targeted treatment of lung cancer. Clinical Lung Cancer, 6(4): 227-236, 2005. (click here to open pubmed link)


Pedersen N, Pedersen MW, Poulsen TT, Mortensen S, Sørensen SB, Rieneck K, Bovin LF, Poulsen HS. New targets and treatment of small cell lung cancer. Chest. 125: 154S, 2004. (click here to open pubmed link)

Collatz HC, Schüz J, Kosteljanetz M, Poulsen HS, Thomsen J, Johansen C. Cellular telephone use and risk for acoustic neurinoma. Am J Epidemiol. 159(3): 277-83, 2004. (click here to open pubmed link)

Pedersen MW, Tkach V, Pedersen N, Berezin V and Poulsen HS. A naturally occuring constitutive active variant of the epidermal growth factor receptor increases cell motility. Int. J. Cancer 108:943-653, 2004. (click here to open pubmed link)


Heidenreich AV, Westmeier R, Pedersen N, Poulsen HS, Kristensen HG. Preparation and purification of cationic nanospheres - effects on particle size, physical stability and cell toxicity. Int. J. Pharm. 254:83-87, 2003. (click here to open pubmed link)

Schimiegelow M, Feldt-Rasmussen U, Rasmussen AK, Lange M, Poulsen HS, Müller J. Assessment of the Hypothalamo-Pituitary-Adrenal Axis in Patients treated with Cranial Radiotherapy for a Childhood Brain Tumor. J Clin Endocrinol Metab. Jul. 88(7):3149-54, 2003. (click here to open pubmed link)

Nielsen KL, Allen MR, Bloomfield SA, Andersen TL, Chen X, Xu T, Poulsen HS, Young MF, Heegaard M. Biglycan Deficiency interferes with overiectomy-induced bone loss. J Bone Miner Res. 18(12):2152-2158, 2003. (click here to open pubmed link)




The Finsencenter, Section 6321, Copenhagen University Hospital, Blegdamsvej 9, DK-2100 Copenhagen, Denmark